Subscribe

Spotlight -

This Year In Medicine 2025

Frank C. Sciurba, MD

Articles by Frank C. Sciurba, MD

Tozorakimab Cuts COPD Exacerbations Across Eosinophil Levels: Frank Sciurba, MD

Tozorakimab Cuts COPD Exacerbations Across Eosinophil Levels: Frank Sciurba, MD

ByFrank C. Sciurba, MD

September 8th 2026

Sciurba, of University of Pittsburgh, discusses full phase 3 OBERON and TITANIA results, including stronger responses in current smokers.

OBERON and TITANIA Showcase Tozorakimab's Emerging Benefit for COPD, With Frank Sciurba, MD

OBERON and TITANIA Showcase Tozorakimab's Emerging Benefit for COPD, With Frank Sciurba, MD

ByFrank C. Sciurba, MD

April 27th 2026

The phase 3 trials enrolled frequent exacerbators regardless of eosinophil count or smoking status.

Reducing COPD Exacerbations With Tozorakimab, With Frank Sciurba, MD

Reducing COPD Exacerbations With Tozorakimab, With Frank Sciurba, MD

ByFrank C. Sciurba, MD

April 17th 2026

Tozorakimab significantly reduced moderate-to-severe exacerbations in COPD regardless of blood eosinophil count.

Expanding Precision Medicine in COPD With Mepolizumab, with Frank Sciurba, MD

Expanding Precision Medicine in COPD With Mepolizumab, with Frank Sciurba, MD

ByFrank C. Sciurba, MD

June 4th 2025

Sciurba shared his excitement for the recent approval of mepolizumab for people with COPD and an eosinophilic phenotype.

Latest Updated Articles

Trending on HCPLive

New Injectable Substantially Reduces Visceral Adipose Tissue in Obesity

Remibrutinib Receives FDA Approval for Symptomatic Dermographism

RELIEVE-AD-PEDs: Dupilumab Sustains Adolescent Atopic Dermatitis Control at 1 Year

Top Reason for Leaving HAE Attacks Untreated, Survey Finds

Residual Asthma Exacerbations on Biologics Vary by Mechanism